TNFRSF17 and Miyoshi myopathy: Monoclonal antibody-based therapies existed great promise in MM.43Recently, tabalumab (LY2127399), with neutralizing activity against BAFF, was found to be well tolerated and showed a better response when combined with bort in relapsed and refractory patients with MM.13 Indeed there are other molecules such as APRIL, BAFF-R,BCMA, and TACI related to BAFF signaling pathway, and particularly APRIL is evidenced playing significant role in MM cell survival and targeting BCMA is in development.